Results 141 to 150 of about 116,963 (259)

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

S-nitrosylation of pVHL regulates β₂ adrenergic receptor function. [PDF]

Proc Natl Acad Sci U S A
Grimmett ZW, Hayashi H, Raffay TM, Lin J, Premont RT, Stamler JS.   +5 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

The Gut Metabolite Phenylacetylglutamine Inhibits the Angiogenic Potential of Human Umbilical Vein Endothelial Cells Via the β-Adrenergic Receptor-LDHA Axis. [PDF]

J Cardiovasc Transl Res
Zhang Y, Yang W, Zhang J, A J, Shen J, Qi Z, Qian J, Sun A, Ge J, Zhang S.   +9 more
europepmc   +1 more source

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

BACH2 links β1-adrenergic receptor/β-arrestin1 signaling to MIAT to inhibit cardiac fibroblast activation and cardiomyocyte apoptosis. [PDF]

Cell Death Discov
Moukette B, Teoh JP, Hashmi WJ, Kawaguchi S, Aonuma T, Moustapha H, Welc SS, Conway SJ, Liangpunsakul S, Yang L, Desai AA, Kim IM.   +11 more
europepmc   +1 more source

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

Adrenergic Receptor [PDF]

, 2020
openaire   +1 more source

Finn Waagstein and the paradigm shift in the treatment of heart failure with β-adrenergic receptor antagonists ('β-blockers'). [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Lorenz K, Ravens U.
europepmc   +1 more source

Reassessing Perioperative Management Strategies for Phaeochromocytoma and Paraganglioma Resections

ANZ Journal of Surgery, EarlyView.
Jun Wei Chong, Simon Harper, Stephanie Manning, Rosemary M. Hall   +3 more
wiley   +1 more source